Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare IVIG payments

Executive Summary

HHS is directed to conduct a study to determine the extent to which intravenous immune globulin could be provided and reimbursed for outpatient use under Medicare as part of the Balanced Budget Act refinements included in the omnibus spending bill. Congress has asked that the department "(A) consider the sites of service that other payors, including Medicare+Choice plans, use for these drugs and biologicals; (B) determine whether covering the delivery of these drugs and biologicals in a Medicare patient's home raises any additional safety and health concerns for the patient; (C) determine whether covering the delivery of these drugs and biologicals in a patient's home can reduce overall spending under the Medicare program; and (D) determine whether changing the site of setting for these services would affect beneficiary access to care." HHS is directed to submit the report to Congress within 18 months of enactment of the bill

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts